Abstract
Background Gestational diabetes mellitus (GDM) can result in increased placental lesions related to high maternal blood glucose, but these relationships are not well understood.
Objective To examine the relationship between GDM and placental vascular malperfusion lesions: accelerated villous maturation, increased syncytial knots, delayed villous maturation, and increased fibrin deposition.
Search strategy PubMed, BIOSIS, and Web of Science databases were systematically searched for full-text articles in English from inception until August 21, 2024.
Selection criteria Our inclusion criteria were randomized controlled trials, case-control, cohort, and cross-sectional studies that examined the relationship between GDM and selected placental vascular malperfusion lesions. The outcome must have been reported as a total proportion.
Data collection and analysis We included all eligible studies in narrative synthesis. If an outcome of interest was in at least three studies, we calculated the odds ratios (OR) by GDM diagnosis, with 95% confidence intervals, using mixed-effects logistic regression with random study effects. We evaluated the risk of bias with the Newcastle-Ottawa Scale.
Main results We screened 151 studies, of which eight were included (n=1,291), and six met the criteria for meta-analysis (n=561). Unadjusted odds (95% confidence interval) of delayed villous maturation were six-fold higher (OR: 6.37 [3.28, 12.37]) in pregnancies with GDM compared to those without GDM. The narrative synthesis of the literature found higher proportions of increased syncytial knots, delayed villous maturation, and increased fibrin deposition, but not accelerated villous maturation, in pregnancies with versus without GDM.
Conclusions GDM was associated with increased risk of three placental malperfusion lesions, although there is a small number of studies in this area. Future investigations should examine if these vascular malperfusions are associated with adverse pregnancy outcomes often linked with GDM.
Synopsis GDM is associated with increased syncytial knots, delayed villous maturation, and increased fibrin deposition, but not accelerated villous maturation.
Funding Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of the Maternal Child Health Bureau Nutrition Training Grant, The TRANSCEND Program in Maternal Child Health Nutrition (T7949101).
Registration Registered in PROSPERO under protocol number CRD42023449651
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=449651
Funding Statement
A portion of the time preparing this manuscript was supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of the Maternal Child Health Bureau Nutrition Training Grant, The TRANSCEND Program in Maternal Child Health Nutrition (T7949101; PI: Bruening). The contents are those of the authors and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS or the U.S. Government.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
PubMed, BIOSIS, and Web of Science or were manually searched by reviewing the reference list of published studies. Search strategies are available in the supplementary files.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos